{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"56.8","upperLimit":"83.5","value":"68.9"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"}],"units":"Participants"}],"description":"Time from infusion to the first of event or censoring Events = Relapse, No Response, or Death; Censoring =Initiation of New Anticancer Therapy, Last Day of Follow-up/EOS; whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL","id":"OG000","title":"Cohort A"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Number of Subjects With Event-Free Survival in Patients With Newly Diagnosed VHR B-ALL or High-risk Relapse of B-ALL 1 Year After Treatment.","type":"PRIMARY","unitOfMeasure":"percentage of subjects"}